JP2025517629A - 複素環式化合物、その組成物、及びそれを用いた治療方法 - Google Patents

複素環式化合物、その組成物、及びそれを用いた治療方法 Download PDF

Info

Publication number
JP2025517629A
JP2025517629A JP2024564800A JP2024564800A JP2025517629A JP 2025517629 A JP2025517629 A JP 2025517629A JP 2024564800 A JP2024564800 A JP 2024564800A JP 2024564800 A JP2024564800 A JP 2024564800A JP 2025517629 A JP2025517629 A JP 2025517629A
Authority
JP
Japan
Prior art keywords
compound
mmol
substituted
unsubstituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517629A5 (enExample
Inventor
ユー、チャオ
スン、ハンズー
ワン、ツァ
ワン、ジウェイ
Original Assignee
ベイジーン スイッツァランド ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベイジーン スイッツァランド ゲーエムベーハー filed Critical ベイジーン スイッツァランド ゲーエムベーハー
Publication of JP2025517629A publication Critical patent/JP2025517629A/ja
Publication of JP2025517629A5 publication Critical patent/JP2025517629A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024564800A 2022-05-05 2023-05-04 複素環式化合物、その組成物、及びそれを用いた治療方法 Pending JP2025517629A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022090877 2022-05-05
CNPCT/CN2022/090877 2022-05-05
PCT/CN2023/092047 WO2023213271A1 (en) 2022-05-05 2023-05-04 Heterocyclic compounds, compositions thereof, and methods of treatment therewith

Publications (2)

Publication Number Publication Date
JP2025517629A true JP2025517629A (ja) 2025-06-10
JP2025517629A5 JP2025517629A5 (enExample) 2026-05-14

Family

ID=88646299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564800A Pending JP2025517629A (ja) 2022-05-05 2023-05-04 複素環式化合物、その組成物、及びそれを用いた治療方法

Country Status (5)

Country Link
US (1) US20250066372A1 (enExample)
EP (1) EP4519267A4 (enExample)
JP (1) JP2025517629A (enExample)
CN (1) CN119156389A (enExample)
WO (1) WO2023213271A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025024388A1 (en) 2023-07-21 2025-01-30 Accutar Biotechnology Inc. Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors
WO2025024726A1 (en) * 2023-07-26 2025-01-30 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinase
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CA2954189A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
WO2020140052A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
EP3956031A1 (en) * 2019-04-19 2022-02-23 Pfizer Inc. Anti-proliferative agents for treating pah
CN112125911B (zh) * 2020-09-24 2022-08-09 深圳湾实验室坪山生物医药研发转化中心 Cdk9抑制剂及其制备方法与应用

Also Published As

Publication number Publication date
WO2023213271A1 (en) 2023-11-09
US20250066372A1 (en) 2025-02-27
CN119156389A (zh) 2024-12-17
EP4519267A4 (en) 2026-02-25
EP4519267A1 (en) 2025-03-12

Similar Documents

Publication Publication Date Title
KR20250047379A (ko) 헤테로시클릭 화합물, 이의 조성물, 및 이를 이용한 치료 방법
KR102387316B1 (ko) Mdm2 단백질 분해제
US20250101028A1 (en) Heterocyclic compounds, compositions thereof, and methods of treatment therewith
US20250221996A1 (en) Heterocyclic compounds, compositions thereof, and methods of treatment therewith
JP6776378B2 (ja) Ｃｏｔモジュレーターとしての４，６−ジアミノキナゾリン類およびその使用方法
US20250250287A1 (en) Heterocyclic compounds, compositions thereof, and methods of treatment therewith
JP5976828B2 (ja) Ｂｔｋ活性阻害剤としてのアルキル化ピペラジン化合物
RU2628616C2 (ru) Бициклические соединения пиперазина
US20250262222A1 (en) Heterocyclic compounds, compositions thereof, and methods of treatment therewith
CN102971317B (zh) 四氢-吡啶并-嘧啶衍生物
KR102616249B1 (ko) 신경영양성 인자인 티로신 키나제 수용체 억제제로서 사용되는 아미노 피라졸로피리미딘 화합물
JP6165977B2 (ja) ヘテロアリールピリドン及びアザ−ピリドンアミド化合物
US20250066372A1 (en) Heterocyclic compounds, compositions thereof, and methods of treatment therewith
IL299415A (en) Pyrimidine-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
HUE025173T2 (hu) Heteroaril-szubsztituált pirrollo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JP2022518505A (ja) Ｔｙｋ２阻害剤およびその使用
WO2025168072A1 (en) Heterocyclic compounds, compositions thereof, and methods of treatment therewith
AU2021351093A9 (en) Compound as akt kinase inhibitor
US20250163047A1 (en) Heterocyclic compounds, compositions thereof, and methods of treatment therewith
CA3191362C (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
CN119462641A (zh) 用于制备杂环化合物的方法
BR112019014191B1 (pt) Composto e composição farmacêutica
BR112019008656B1 (pt) Composto de aminopirazolopirimidina, composição farmacêutica que compreende o mesmo e uso do dito composto para a profilaxia ou o tratamento de uma doença mediada por receptor de tirosina quinase de fator neurotrófico
BR112019014191A2 (pt) Composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar doenças do sistema imunológico.

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250106

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260501